Farms.com Home   Farm Equipment News

Deere Announces Layoffs of Production Employees at Ottumwa, Iowa Plant

The new year for Deere & Co. started with the announcement of another round of layoffs, this time impacting approximately 75 production employees who will be placed on indefinite layoff effective Feb. 7 at its plant in Ottumwa, Iowa. Multiple media outlets across Iowa reported that an announcement on the state’s Worker Adjustment and Retraining Notification, or WARN, site came on Jan. 6 after the company temporarily shut down production in Ottumwa beginning in December reported by Farm Equipment at the time, as a result of a reduction in customer demand.

According to a DesMoines Register news update from Kevin Baskins, the latest cut is Deere’s 15th announced layoff over the past year. Based in Moline, Ill.,, Deere & Co. operates plants across Iowa, where the layoffs have affected 1,866 workers at facilities in Waterloo, Davenport, Dubuque, Ankeny, Johnson, Urbandale and Ottumwa. The article also noted that in a statement issued Jan. 6, Deere again referred to “challenging market conditions” which resulted in reduced demand for its equipment.

As reported in Farm Equipment’s coverage of Deere’s most recent earnings report, the company reported that those ongoing challenging market conditions resulted in a marked reduction of demand for equipment and projected earnings to be down $5 billion from 2023. The company says workforce adjustments will continue to be made as needed pending future equipment demand.

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.